NEW YORK (GenomeWeb News) – The Oxford Biomedical Research Centre will install several 454 GS FLX sequencing instruments and will use NimbleGen arrays to conduct genome-wide studies focused on finding links between human diseases and genetic mutations, 454 and NimbleGen parent company Roche said Thursday.
OxBRC is a partnership between Oxford Radcliffe Hospitals NHS Trust and the University of Oxford.
Oxford will use the NimbleGen arrays as a preparative tool for sequencing and genome-wide studies of samples with clinical documentation for selected diseases in three areas.
The researchers will sequence several genes for private familial mutations, they will conduct mutation screening in a large number of genes using both the 454 and NimbleGen technologies, and they will seek to identify genes and regions with genomic imbalances using the NimbleGen CGH Arrays.
Financial terms of the agreement were not released.